2126.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Jun 2024 @ 23:45):

Stats
Today's Volume	195 500
Average Volume	509 271
Market Cap	904.37M
EPS	HKD0 ( 2024-04-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-1.090
ATR14	HKD0.0140 (0.62%)

Volume Correlation

Long: 0.19 (neutral)

Short: -0.38 (neutral)

Signal:(49.551) Neutral

JW THERAP-B Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

JW THERAP-B Correlation - Currency/Commodity

-0.60
( weak negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.38
( neutral )

0.03
( neutral )

JW THERAP-B Financials

Annual	2023
Revenue:	HKD173.86M
Gross Profit:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2023
Revenue:	HKD173.86M
Gross Profit:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2022
Revenue:	HKD145.70M
Gross Profit:	HKD58.76M (40.33 %)
EPS:	HKD-2.06

FY	2021
Revenue:	HKD30.80M
Gross Profit:	HKD9.05M (29.37 %)
EPS:	HKD-5.32

Financial Reports:

No articles found.

JW THERAP-B Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

JW THERAP-B

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.